Formulary

Name: Formulary
Brand: Formula Kino

Formulary is an AI-supported fund administration platform that combines managed fund administration services with software to improve data quality, operational workflows, and investor/LP reporting for private markets asset managers.

Website

Published Sep 20, 2026

01Common complaints

- When you need high confidence from public third-party reviews - If your investment committee or procurement requires Gartner Peer Insights / G2 / TrustRadius depth, Formulary currently appears to lack that public review footprint. - When you need ultra-broad global coverage and long-established operational playbooks - Very large, multi-jurisdiction structures, complex derivatives/valuation requirements, or highly specialized reporting may be better served by large incumbents (e.g., SS&C, Apex Group) depending on requirements. - When pricing transparency is a must - If you require published pricing tiers and self-serve buying, Formulary’s model appears sales-led/quote-based. - When your security/compliance team needs public evidence of multiple certifications - Formulary publicly states SOC 2 Type II certification, but ISO certifications and detailed controls are not clearly published; teams requiring these publicly may prefer vendors with mature trust centers and extensive published documentation. - Publicly documented limitations - No explicit public roadmap or "known limitations" page was found in accessible sources. - Likely limitations / unknowns to clarify - Roadmap maturity - What is automated now versus planned - Scale limitations - Maximum LP counts / fund complexity supported without service degradation - API / integrations - The existence of a status page referencing an API suggests an API surface, but public API documentation was not located in accessible sources.

Deal disqualifiers: what makes a POOR fit

Buyer requires extensive independent reviews and a long multi-year operating history
Ultra-complex global structures where incumbents’ specialized coverage is required
Procurement requires ISO certifications or detailed public documentation not currently published

02Why they buy

- Claimed differentiators (validate in diligence) - The vendor describes the use of AI and automation to support fund administration workflows. - The vendor emphasizes addressing data inaccuracies and improving client service compared with some legacy providers. - The vendor-published materials include an example where they report finding material inaccuracies in an incumbent administrator's outputs. - Where competitors clearly have advantages - Incumbents - Longer operating history - Larger teams, broader jurisdictional coverage - More publicly visible customer base - Carta - Broader adjacent product suite and platform consolidation strategy

03Field reports

Important context on review availability

Formulary (vendor homepage) appears to be a relatively new B2B provider (launch narrative in 2025–2026). Public third-party review coverage on enterprise review platforms (G2/TrustRadius/Gartner Peer Insights) appears limited or not readily discoverable for this product.
A G2 presence found during research relates to a different entity, so it was not treated as a reliable review source for Formulary Financial.

Vendor-published testimonials (vendor-published; not independently verified)

- On Formulary’s homepage and CEO letter and company blog pages, the company includes testimonials asserting that a review uncovered inaccuracies from an incumbent administrator, including a claim that the review uncovered inaccuracies that could have resulted in significant financial losses. - Critical note - This is a vendor-published assertion without a disclosed methodology, customer name, or independent validation in the public sources reviewed.

Independent review platforms (Gartner Peer Insights, G2, TrustRadius)

- Gartner Peer Insights - Attempted to locate a Formulary Financial listing; no accessible product-specific review page was located in this research pass. - Note: Gartner Peer Insights requires vendor listing and has verification processes; absence may reflect newness or naming differences. - G2 - No clear Formulary Financial review listing was found; search results surfaced an unrelated entity. - TrustRadius - No clear Formulary Financial product profile or reviews were found in accessible sources during this research pass.

Community/social discussion signals (limited product-specific; more category pain)

Reddit and other public discussions are rich in unrelated "formulary" content; product-specific community discussions for Formulary Financial were not prominent in the accessible community sources during this research pass.

What this means for a buyer

Because independent reviews are scarce, diligence should lean more heavily on:
- Reference calls with named customers
- Security documentation review
- Pilot / proof-of-concept scope
- Contract protections (SLAs, exit support, data export formats)

Vendor-published examples

CEO letter/article includes an anecdote claiming the vendor identified inaccuracies in an incumbent fund administrator's outputs with potential significant financial implications.

Critical evaluation

No customer name, no public documentation of error type (e.g., allocations, fee calculations, FX, waterfall), and no disclosed validation method.
Treat as a directional signal (they are willing to review incumbent outputs), not as proven ROI.

What to request in diligence (practical)

A redacted sample reporting package (quarterly, annual)
An example of an exception log and resolution process
A sample reconciliation package (bank, positions, capital activity)

04Best fit

Company sizes

Most plausible ICP (inferred)
- Emerging to mid-sized private market managers (small to mid-sized firms) that need institutional-grade administration but seek improved data quality and client service relative to some legacy providers.

Industries and verticals

Private markets
- Venture capital
- Private equity
- Private credit
- Real assets (depending on coverage)

Roles and personas

Decision makers
- COO / Head of Operations
- CFO / Finance Director
- Managing Partner (emerging managers)
End users
- Fund accountants
- Investor relations / LP ops
- Compliance teams (coordination with filings)

Pain points the product addresses

Operational burden of fund reporting and investor communications
Data inaccuracies or reconciliation friction with current administrators
Slow responsiveness and long turnaround times from incumbent providers

Qualification criteria: what makes a GREAT fit

Manager that values speed, transparency, and data lineage
Willingness to adopt a newer provider in exchange for potential operational improvements
Desire for a combined service + software relationship

05The pitch

What the product does (core value proposition in objective terms)

- Formulary describes its product as using artificial intelligence to support fund administration for private markets asset managers (e.g., PE/VC/credit/real assets). The offering combines service delivery (fund administration) with software aimed at improving data quality, operational workflows, and investor/LP reporting. - The company’s homepage messaging highlights themes including reliable data, fund operations tooling, and targeted insights for asset managers to manage and grow their businesses. - Vendor messaging frames the problem as unreliable data and poor client service in traditional fund administration.

Target market and market positioning

- Target market - Private markets asset managers (emerging to mid-size managers, and potentially larger managers seeking improved data quality and service). - Positioning - The vendor positions itself as an alternative to legacy fund administrators and tech-enabled administrators, describing a focus on using AI and automation to support operational processes. - Differentiation is primarily claimed around automation, data quality controls, and a more hands-on client service model.

Get a comprehensive analysis of Formulary including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →